Related Experiment Video
Updated: Aug 9, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 3, 2013
Noncoding RNA for personalized prostate cancer treatment: utilizing the 'dark matters' of the genome
Junjie Hua1,2, Jennifer Lu1,3, Keren Isaev1,2
1Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Abstract:
Prostate cancer is the most commonly diagnosed cancer in men in western countries, with significant health impact. Clinically, it is complicated with the lack of biomarkers and effective treatments for aggressive disease, particularly castration-resistant prostate cancer. Although we have gained much insight into the biology of prostate cancer through studying protein-coding genes, they represent only a small fraction of our genome. Therefore, it is essential for us to investigate noncoding RNAs, which comprise the majority of our transcriptome, in order to achieve a better understanding of prostate cancer and move toward personalized medicine. In this article, we will address recent advancements in our knowledge of noncoding RNAs, and discuss the clinical potentials and challenges of different types of noncoding RNAs in prostate cancer.
Insights
Investigating noncoding RNAs is crucial for understanding prostate cancer, especially aggressive forms. Research into these genetic elements offers new hope for improved diagnostics and treatments.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Prostate cancer is a leading cancer diagnosis in men globally.
- Current treatments and biomarkers for aggressive prostate cancer, including castration-resistant prostate cancer, are limited.
- Protein-coding genes, a small part of the genome, have been extensively studied, leaving noncoding RNAs largely unexplored.
Purpose of the Study:
- To review recent advancements in understanding noncoding RNAs in prostate cancer.
- To discuss the clinical potential of noncoding RNAs for diagnosis and treatment.
- To highlight challenges associated with noncoding RNA-based therapies.
Main Methods:
- Literature review of recent studies on noncoding RNAs in prostate cancer.
- Analysis of different types of noncoding RNAs (e.g., microRNAs, long noncoding RNAs).
- Discussion of clinical applications and therapeutic strategies.
Main Results:
- Noncoding RNAs play significant roles in prostate cancer development and progression.
- Specific noncoding RNAs show promise as diagnostic biomarkers.
- Targeting noncoding RNAs presents potential therapeutic avenues for prostate cancer.
Conclusions:
- Noncoding RNAs are critical regulators in prostate cancer.
- Further research is needed to overcome challenges and realize the clinical potential of noncoding RNAs.
- Noncoding RNA-based approaches could lead to personalized medicine for prostate cancer patients.
